Introduction {#s1}
============

As the fourth leading cause of cancer deaths and the fifth most common diagnosed cancer in China in 2009 [@pone.0096958-Chen1], the 5-year-survival rate of esophageal cancer is very poor and accounts only 12.3% in 23 European countries [@pone.0096958-Berrino1]. More than 90% esophageal cancers are esophageal squamous cell carcinoma (ESCC). In addition to environmental risk factors such as smoking and heavy drinking, single nucleotide polymorphisms (SNPs) as genetic factors might play an important role in ESCC carcinogenesis [@pone.0096958-Gu1].

Tumor suppressor protein p53 is frequently mutated in diverse types of cancers and is implicated in cell proliferation and tumor progression [@pone.0096958-Soussi1]. The *p53* gene is on chromosome 17p13.1. A well-studied *p53* polymorphism, Arg72Pro (rs1042522 C/G; R/P) has been reported to have functional significance [@pone.0096958-Sinilnikova1], [@pone.0096958-Dumont1]. Compared with Arg wild-type protein, the Pro variant allele encoded protein is more efficient in inducing nuclear DNA repair genes expression [@pone.0096958-Altilia1]. Polymorphism *p53* rs1042522 G\>C has been associated with risk of numerous kinds of cancers [@pone.0096958-Whibley1].

P21 (Waf1/Cip1/CDKN1A), a non-specific cdk inhibitor and a key mediator of G0-G1 cell cycle arrest, is upregulated by wild-type p53. p21 functions during gene repair and angiogenesis [@pone.0096958-Weiss1]. Cell cycle arrest at the G1-S phase restriction point is mediated through p21 up-regulation induced by p53, and the associated G1 cyclins-cdk2 complexes inhibition [@pone.0096958-Keshava1]. In p53-deficient cells, p21 interacts with proliferating cell nuclear antigen (PCNA) and causes both G1 and G2 cell cycle arrest [@pone.0096958-Kaul1]. By inhibiting PCNA-dependent DNA replication, p21 expression can suppress tumor growth and mismatch repair in vitro [@pone.0096958-Li1]. *p21* encodes a 21-kDa protein, is located on chromosome 6p21.2 and consists of three exons and two introns [@pone.0096958-elDeiry1].

Tumor protein 53-binding protein 1 (TP53BP1) interacts specifically with *p53* and participates in both DNA repair and cell cycle control. By cooperating with damage sensors and signal transducers, TP53BP1 helps mediate the DNA damage checkpoint [@pone.0096958-Iwabuchi1].

*P73* shares structural and functional similarities to *p53*. *p73* is located at 1p36.33, mapping to a region that is often deleted in cancers [@pone.0096958-Kaghad1]. p73 activates transcription of p21- and p53-responsive genes, which participate in cell cycle control, DNA repair, apoptosis and inhibits cell growth in a p53-like manner by inducing apoptosis or G1 cell cycle arrest [@pone.0096958-Flores1], [@pone.0096958-Jost1]. This suggests that p73 has tumor-suppressor functions. Otherwise, the *p73* gene has some significant differences from p53. In contrast to p53-deficient mice, those lacking *p73* show no increased susceptibility to spontaneous tumorigenesis [@pone.0096958-Mai1].

Genetic variations in the p53 pathway genes, such as *p21*, *p53*, *TP53BP1* and *p73*, may contribute to the development of ESCC. In a hospital-based case-control study, we performed genotyping analyses of eight functional *p21*, *p53*, *TP53BP1* and *p73* SNPs in 629 ESCC cases and 686 controls in a Chinese population.

Materials and Methods {#s2}
=====================

Ethical approval of the study protocol {#s2a}
--------------------------------------

The data has been deposited in Supporting Information files. Regarding ethical conduct of research involving human subjects and/or animals, we complied with the World Medical Association Declaration of Helsinki. The review Board of Jiangsu University (Zhenjiang, China) approved this hospital-based case-control study. Written informed consent was provided by all subjects in the study.

Patients and controls {#s2b}
---------------------

Between October 2008 and December 2010, from the Affiliated People\'s Hospital of Jiangsu University and Affiliated Hospital of Jiangsu University (Zhenjiang, China), 629 subjects with esophageal cancer were recruited consecutively. By pathological means, all cases of esophageal cancer were diagnosed as ESCC. Exclusion criteria were: patients who previously had cancer; any metastasized cancer and radiotherapy or chemotherapy. 686 patients without cancer were matched to the cases with regard to age (±5 years) and sex, as controls. The controls were recruited from the above-mentioned two hospitals at the same time period. Most of the controls were being treated for trauma (including 612 trauma patients, 45 infectious disease patients and 29 hypertension patients).

Using a pre-tested questionnaire, trained interviewers questioned each subject personally and obtained demographic data information (e.g., age, sex) and related risk factors (such as tobacco smoking and alcohol consumption). Venous blood samples (2-mL) were collected after the interview from each subject. The definition of "smokers" was smoking one cigarette per day for \>1 year. The definition of "alcohol drinkers" was consumption ≥3 alcoholic drinks a week for \>6 months.

Isolation of DNA, SNPs selection and genotyping by ligation detection reaction (LDR) {#s2c}
------------------------------------------------------------------------------------

From whole blood, genomic DNA was isolated [@pone.0096958-Wei1]. The 8 SNPs selection was based on previous published articles with functional consideration [@pone.0096958-Wang1], [@pone.0096958-Dahabreh1], [@pone.0096958-Rafnar1], [@pone.0096958-Liu1]. With technical support from the Shanghai Biowing Applied Biotechnology Company, the samples were genotyped using the LDR method [@pone.0096958-Chen2]. In 160 (12.17%) randomly selected samples with high DNA quality, repeated analyses were done for quality control.

Statistical analyses {#s2d}
--------------------

Using the *χ* ^2^ test, between the cases and controls, the distributions of demographic characteristics, selected variables, and genotypes of the *p21*, *p53*, *TP53BP1* and *p73* variants differences were evaluated. Using logistic regression analyses, the associations between the eight SNPs and risk of ESCC were estimated for crude ORs and adjusted ORs when adjusting for age, sex, smoking and drinking status. Because of the number of comparisons, the Bonferroni correction procedure was applied. By a goodness-of-fit *χ* ^2^ test, the Hardy-Weinberg equilibrium (HWE) was tested to compare the observed genotype frequencies to the expected ones among the control subjects. With SAS 9.1.3 (SAS Institute, Cary, NC, USA), all statistical analyses were performed.

Results {#s3}
=======

Characteristics of the study population {#s3a}
---------------------------------------

Cases and controls\' characteristics are summarized in [Table 1](#pone-0096958-t001){ref-type="table"}. By the *χ* ^2^ tests, the cases and controls are adequately matched on age and sex. Between the cases and the controls, significant difference was detected on smoking and drinking status, which is shown in [Table 1](#pone-0096958-t001){ref-type="table"}. The primary information for eight genotyped SNPs was in [Table 2](#pone-0096958-t002){ref-type="table"}. The concordance rates of repeated analyses were 100% except *p21* rs3176352 G\>C (158/160, 98.75%). For all SNPs, minor allele frequency (MAF) in our controls was similar to MAF for Chinese in database. In the controls, for these eight polymorphisms, the observed genotype frequencies were all in HWE ([Table 2](#pone-0096958-t002){ref-type="table"}).

10.1371/journal.pone.0096958.t001

###### Distribution of selected demographic variables and risk factors in ESCC cases and controls.

![](pone.0096958.t001){#pone-0096958-t001-1}

  Variable                     Cases (n = 629)   Controls (n = 686)   *p* [a](#nt101){ref-type="table-fn"}          
  --------------------------- ----------------- -------------------- -------------------------------------- ------- -------------
  **Age (years)** mean ± SD     62.85 (±8.13)      62.58 (±7.89)                     0.541                          
  **Age (years)**                                                                                                       0.155
  \<63                               310               49.28                          365                    53.21  
  ≥63                                319               50.72                          321                    46.79  
  **Sex**                                                                                                               0.185
  Male                               444               70.59                          461                    67.20  
  Female                             185               29.41                          225                    32.80  
  **Tobacco use**                                                                                                    **\<0.001**
  Never                              355               56.44                          499                    72.74  
  Ever                               274               43.56                          187                    27.26  
  **Alcohol use**                                                                                                    **\<0.001**
  Never                              428               68.04                          526                    76.68  
  Ever                               201               31.96                          160                    23.32  

Two-sided *χ* ^2^ test and student t test; Bold values are statistically significant (*p* \<0.05).

10.1371/journal.pone.0096958.t002

###### Primary information for *p21*, *p53*, *TP53BP1* and *p73* polymorphisms.

![](pone.0096958.t002){#pone-0096958-t002-2}

  Genotyped SNPs                                                            *p21* rs2395655 G\>A   *p21* rs1059234 C\>T   *p21* rs3176352 G\>C   *p21* rs1801270 C\>A   *p21* rs762623 C\>A   *p53* rs1042522 G\>C   *TP53BP1* rs560191 G\>C   *p73* rs1801173C\>T
  ------------------------------------------------------------------------ ---------------------- ---------------------- ---------------------- ---------------------- --------------------- ---------------------- ------------------------- ---------------------
  Chromosome                                                                         6                      6                      6                      6                      6                     17                      15                       1
  Gene Official Symbol                                                             CDKN1A                 CDKN1A                 CDKN1A                 CDKN1A                CDKN1A                  TP53                   TP53BP1                  TP73
  Function                                                                         5-UTR                  3-UTR              intron region             missense            intron region            missense                missense                  5-UTR
  Chr Pos (Genome Build 36.3)                                                     36753674               36761575               36760317               36759949              36753444               7520197                 41555066                 3588770
  Regulome DB Score[a](#nt102){ref-type="table-fn"}                                  1f                     4                      4                      3a                    1b                     5                       1f                       5
  TFBS[b](#nt103){ref-type="table-fn"}                                               Y                     ---                    ---                    ---                     Y                    ---                      ---                     ---
  Splicing (ESE or ESS)                                                             ---                     Y                     ---                    ---                    ---                   ---                       Y                       Y
  miRNA (miRanda)                                                                   ---                     Y                     ---                    ---                    ---                   ---                      ---                     ---
  miRNA (Sanger)                                                                    ---                     Y                     ---                    ---                    ---                   ---                      ---                     ---
  MAF[c](#nt104){ref-type="table-fn"} for Chinese in database                      0.465                  0.453                  0.422                  0.465                  0.111                 0.489                    0.444                   0.267
  MAF in our controls (n  =  686)                                                  0.473                  0.478                  0.410                  0.479                  0.112                 0.436                    0.447                   0.230
  *p* value for HWE[d](#nt105){ref-type="table-fn"} test in our controls           0.606                  0.234                  0.443                  0.639                  0.852                 0.372                  **0.009**                 0.739
  Genotyping method[e](#nt106){ref-type="table-fn"}                                 LDR                    LDR                    LDR                    LDR                    LDR                   LDR                      LDR                     LDR
  \% Genotyping value                                                              95.13%                 95.13%                 96.81%                 98.63%                98.63%                 96.35%                  96.43%                  96.81%

http://[www.regulomedb.org/](http://www.regulomedb.org/);

TFBS: Transcription Factor Binding Site (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>);

MAF: minor allele frequency, *p73* rs1801173 C\>T MAF is in CHB+JPT population;

HWE: Hardy--Weinberg equilibrium;

LDR: ligation detection reaction; Bold values are statistically significant (*p*\<0.05).

Associations between p21, p53, TP53BP1 and p73 polymorphisms and risk of ESCC and genotype combination analysis {#s3b}
---------------------------------------------------------------------------------------------------------------

When the *p21* rs3176352 GG homozygote genotype was used as the reference group, the GC genotype was not associated with the risk for ESCC; the CC genotype was associated with a significantly increased risk for ESCC (CC vs. GG: adjusted OR = 1.61, 95% CI = 1.18--2.20, *p* = 0.0030). In the dominant model, the *p21* rs3176352 GC/CC variants were not associated with the risk of ESCC, compared with the *p21* rs3176352 GG genotype. In the recessive model, when the *p21* rs3176352 GG/GC genotypes were used as the reference group, the CC homozygote genotype was associated with a 63% increased risk of ESCC (CC vs. GG/GC: adjusted OR = 1.63, 95% CI = 1.23--2.15, *p* = 0.0006) ([Table 3](#pone-0096958-t003){ref-type="table"}).

10.1371/journal.pone.0096958.t003

###### Logistic regression analyses of associations between *p21*, *p53*, *TP53BP1* and *p73* polymorphisms and risk of ESCC.

![](pone.0096958.t003){#pone-0096958-t003-3}

  Genotype                                                      Cases (n = 629)   Controls (n = 686)   Crude OR (95%CI)   *p*    Adjusted OR [a](#nt107){ref-type="table-fn"} (95%CI)       *p*                                   
  ------------------------------------------------------------ ----------------- -------------------- ------------------ ------ ------------------------------------------------------ -------------- --------------------------- --------------
  *p21* rs2395655 G\>A                                                                                                                                                                                                            
  GG                                                                  148                24.7                184          28.3                           1.00                                                    1.00             
  GA                                                                  327                54.5                318          48.8                    1.28 (0.98--1.67)                        0.070           1.23 (0.94--1.62)          0.128
  AA                                                                  125                20.8                149          22.9                    1.04 (0.76--1.44)                        0.798           1.00 (0.72--1.39)          0.982
  GA+AA                                                               452                75.3                467          71.7                    1.20 (0.94--1.55)                        0.150           1.16 (0.90--1.50)          0.256
  GG+GA                                                               475                79.2                502          77.1                           1.00                                                    1.00             
  AA                                                                  125                20.8                149          22.9                    0.89 (0.68--1.16)                        0.381           0.87 (0.66--1.15)          0.332
  *p21* rs1059234 C\>T                                                                                                                                                                                                            
  CC                                                                  172                28.7                170          26.1                           1.00                                                    1.00             
  CT                                                                  321                53.5                340          52.2                    0.93 (0.72--1.21)                        0.604           0.88 (0.67--1.15)          0.334
  TT                                                                  107                17.8                141          21.7                    0.75 (0.54--1.04)                        0.086           0.72 (0.51--1.00)          0.050
  CT+TT                                                               428                71.3                481          73.9                    0.88 (0.69--1.13)                        0.311           0.83 (0.64--1.07)          0.149
  CC+CT                                                               493                82.2                510          78.3                           1.00                                                    1.00             
  TT                                                                  107                17.8                141          21.7                    0.79 (0.59--1.04)                        0.090           0.78 (0.59--1.04)          0.089
  *p21* rs3176352 G\>C                                                                                                                                                                                                            
  GG                                                                  191                31.8                239          35.5                           1.00                                                    1.00             
  GC                                                                  258                43.0                316          47.0                    1.02 (0.79--1.31)                        0.868           0.98 (0.76--1.27)          0.866
  CC                                                                  151                25.2                118          17.5                **1.60 (1.18**--**2.18)**                  **0.0026**    **1.61 (1.18**--**2.20)**    **0.0030**
  GC+CC                                                               409                68.2                434          64.5                    1.18 (0.93--1.49)                        0.166           1.15 (0.91--1.46)          0.255
  GG+GC                                                               449                74.8                555          82.5                           1.00                                                    1.00             
  CC                                                                  151                25.2                118          17.5                **1.58 (1.21**--**2.07)**                  **0.0009**    **1.63 (1.23**--**2.15)**    **0.0006**
  *p21* rs1801270 C\>A                                                                                                                                                                                                            
  CC                                                                  179                29.1                182          26.7                           1.00                                                    1.00             
  CA                                                                  322                52.3                346          50.8                    0.95 (0.73--1.22)                        0.672           0.89 (0.68--1.15)          0.373
  AA                                                                  115                18.7                153          22.5                    0.76 (0.56--1.05)                        0.097       **0.72 (0.52**--**0.99)**    **0.044**
  CA+AA                                                               437                70.9                499          73.3                    0.89 (0.70--1.14)                        0.349           0.84 (0.65--1.07)          0.154
  CC+CA                                                               501                81.3                528          77.5                           1.00                                                    1.00             
  AA                                                                  115                18.7                153          22.5                    0.79 (0.60--1.04)                        0.092           0.77 (0.59--1.02)          0.070
  *p21* rs762623 G\>A                                                                                                                                                                                                             
  GG                                                                  480                77.9                537          78.9                           1.00                                                    1.00             
  GA                                                                  129                20.9                136          20.0                    1.06 (0.81--1.39)                        0.667           1.06 (0.81--1.40)          0.675
  AA                                                                   7                 1.1                  8           1.2                     0.98 (0.35--2.72)                        0.967           0.95 (0.33--2.70)          0.923
  GA+AA                                                               136                22.1                144          21.1                    1.06 (0.81--1.38)                        0.683           1.06 (0.81--1.38)          0.700
  GG+GA                                                               609                98.9                673          98.8                           1.00                                                    1.00             
  AA                                                                   7                 1.1                  8           1.2                     0.97 (0.35--2.68)                        0.949           0.94 (0.33--2.67)          0.905
  *p53* rs1042522 G\>C                                                                                                                                                                                                            
  GG                                                                  177                28.8                213          32.6                           1.00                                                    1.00             
  GC                                                                  321                52.3                310          47.5                    1.25 (0.97--1.61)                        0.089           1.19 (0.92--1.54)          0.186
  CC                                                                  116                18.9                130          19.9                    1.07 (0.78--1.48)                        0.663           1.04 (0.75--1.44)          0.810
  GC+CC                                                               437                71.2                440          67.4                    1.20 (0.94--1.52)                        0.144           1.15 (0.90--1.46)          0.273
  GG+GC                                                               498                81.1                523          80.1                           1.00                                                    1.00             
  CC                                                                  116                18.9                130          19.9                    0.94 (0.71--1.24)                        0.648           0.93 (0.70--1.24)          0.639
  *TP53BP1* rs560191 G\>C                                                                                                                                                                                                         
  GG                                                                  213                34.6                216          33.1                           1.00                                                    1.00             
  GC                                                                  291                47.3                290          44.4                    1.02 (0.79--1.31)                        0.891           1.01 (0.78--1.30)          0.959
  CC                                                                  111                18.0                147          22.5                    0.77 (0.56--1.05)                        0.092           0.76 (0.56--1.05)          0.093
  GC+CC                                                               402                65.4                437          66.9                    0.93 (0.74--1.18)                        0.558           0.92 (0.73--1.17)          0.515
  GG+GC                                                               504                82.0                506          77.5                           1.00                                                    1.00             
  CC                                                                  111                18.0                147          22.5                **0.76 (0.58**--**1.00)**                  **0.049**         0.76 (0.57--1.01)          0.055
  *p73* rs1801173 C\>T                                                                                                                                                                                                            
  CC                                                                  311                51.8                401          59.6                           1.00                                                    1.00             
  CT                                                                  251                41.8                235          34.9                **1.38 (1.09**--**1.74)**                  **0.007**     **1.39 (1.10**--**1.76)**    **0.006**
  TT                                                                  38                 6.3                  37          5.5                     1.32 (0.82--2.13)                        0.248           1.27 (0.78--2.07)          0.337
  CT+TT                                                               289                48.2                272          40.4                **1.37 (1.10**--**1.71)**                  **0.006**     **1.37 (1.10**--**1.72)**    **0.006**
  CC+CT                                                               562                93.7                636          94.5                           1.00                                                    1.00             
  TT                                                                  38                 6.3                  37          5.5                     1.16 (0.73--1.85)                        0.527           1.11 (0.69--1.79)          0.667
  *p21* rs3176352 G\>C and *p73* rs1801173 C\>T combinations                                                                                                                                                                      
  No risk variant genotype[b](#nt108){ref-type="table-fn"}            226                37.7                323          48.0                           1.00                                                    1.00             
  Either one risk variant genotype                                    308                51.3                310          46.1                **1.42 (1.13**--**1.79)**                  **0.0030**    **1.42 (1.12**--**1.80)**    **0.0035**
  Both risk variant genotypes                                         66                 11.0                 40          5.9                 **2.36 (1.54**--**3.62)**                 **\<0.0001**   **2.47 (1.60**--**3.82)**   **\<0.0001**

Adjusted for age, sex, smoking status and alcohol consumption;

Risk variant genotype means *p21* rs3176352 CC or *p73* rs1801173 CT/TT; *p21* rs3176352 C vs. G OR = 1.26, 95% CI = 1.08--1.47, *p* = 0.0041; *p73* rs1801173 T vs. C OR = 1.26, 95% CI = 1.05--1.50, *p* = 0.0126. Bonferroni correction (number of mutiple test = 32) was performed to correct the *p* value (*p* ~correct~); for *p21* rs3176352 G\>C, the *p* ~correct~ = 0.096 for CC vs. GG after adjusted for age et al., *p* ~correct~ = 0.0192 for CC vs. GG/GC. For *p73* rs1801173 C\>T, the *p* ~correct~ = 0.202 for CT vs. CC after adjusted for age et al., *p* ~correct~ = 0.195 for CT/TT vs. CC. For the rest 6 SNPs, *p* ~correct~\>0.05 in all comparison models; Bold values are statistically significant (*p*\<0.05).

When the *p73* rs1801173 CC homozygote genotype was used as the reference group, the CT genotype was associated with a significantly increased risk for ESCC (CT vs. CC: adjusted OR = 1.39, 95% CI = 1.10--1.76, *p* = 0.006); the TT genotype was not associated with the risk of ESCC. In the dominant model, the *p73* rs1801173 CT/TT variants were associated with a significantly increased risk for ESCC (CT/TT vs. CC: adjusted OR = 1.37, 95% CI = 1.10--1.72, *p* = 0.006), compared with the *p73* rs1801173 CC genotype. In the recessive model, when the *p73* rs1801173 CC/CT genotypes were used as the reference group, the TT homozygote genotype was not associated with the risk of ESCC ([Table 3](#pone-0096958-t003){ref-type="table"}).

When the *p21* rs1801270 CC homozygote genotype was used as the reference group, the AA genotype was associated with a significantly decreased risk for ESCC. When the *TP53BP1* rs560191 GG/GC genotypes were used as the reference group, the CC genotype was associated with a significantly decreased risk for ESCC ([Table 3](#pone-0096958-t003){ref-type="table"}). Logistic regression analyses revealed that the *p21* rs2395655 G\>A, *p21* rs1059234 C\>T, *p21* rs762623 C\>A and *p53* rs1042522 G\>C polymorphisms were not associated with the risk of ESCC ([Table 2](#pone-0096958-t002){ref-type="table"}). After the Bonferroni correction (number of mutiple test  = 32), for *p21* rs3176352 G\>C, the adjusted *p* = 0.096 for CC vs. GG, adjusted *p* = 0.0192 for CC vs. GG/GC. For *p73* rs1801173 C\>T, the *p* ~correct~ = 0.202 for CT vs. CC after adjusted for age et al., *p* ~correct~ = 0.195 for CT/TT vs. CC. For the rest 6 SNPs, in all comparison models, *p*\>0.05.

When the *p21* rs3176352 CC genotype and *p73* rs1801173 CT/TT genotypes were considered as risk variant genotypes. When the no risk variant genotype carrier group was used as the reference group, the either one risk variant genotype carrier group (adjusted OR = 1.42, 95% CI = 1.12--1.80, *p* = 0.0035) and both risk variant genotypes carrier group (adjusted OR = 2.47, 95% CI = 1.60--3.82, *p*\<0.0001) were associated with a significantly increased risk for ESCC.

Stratification analyses on the p21 rs3176352 G\>C and p73 rs1801173 C\>T polymorphism and the risk of ESCC {#s3c}
----------------------------------------------------------------------------------------------------------

To evaluate the effects of *p21* rs3176352 G\>C genotypes on ESCC risk according to different age, sex, smoking and alcohol drinking status; we performed the stratification analyses. A significantly increased risk of ESCC associated with the *p21* rs3176352 G\>C polymorphism was evident among all subgroups except in female patients after stratification ([Table S1](#pone.0096958.s001){ref-type="supplementary-material"}). A significantly decreased risk of ESCC associated with the *p73* rs1801173 C\>T polymorphism was evident among older patients, female patients and patients who never drinking or smoking ([Table S2](#pone.0096958.s002){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In this hospital-based case-control study of ESCC, we found that the *p21* rs3176352 CC and *p73* rs1801173 CT/TT genotypes were associated with increased risk of ESCC; positive results were also observed in genotype combination analysis. To the best of our knowledge, this is the first positive association of *p21* rs3176352 G/C and *p73* rs1801173 C/T polymorphisms with ESCC risk.

P21 is a cyclin-dependent kinase inhibitor. It has been observed that in a wide variety of cancers, p21 expression is altered. At the G1 phase, the p21 protein disrupts cell cycle progression [@pone.0096958-Gartel1], [@pone.0096958-Harada1]. Binding of the tumor suppressor protein p53 to the p21 promoter inducing p21 expression [@pone.0096958-Abbas1].

*P21* rs3176352 G/C (IVS2+16 G\>C) is located in intron 2 of *p21*, 16 bp downstream from the splicing site. This C-to-G transition is predicted to affect the *p21* messenger RNA splicing [@pone.0096958-Xi1]. Choi *et al.* demonstrated that *p21* rs3176352 G/C polymorphism appeared to be in linkage disequilibrium with Ser31Arg in a Korean population. Analysis of this haplotype for lung cancer susceptibility demonstrated a protective effect that was dependent on the number of variant alleles. In a previous study involving 80 esophageal cancer patients and 200 cancer-free controls from Ningxia Region of China, the *p21* rs3176352 G/C polymorphism was not associated with esophageal cancer risk [@pone.0096958-Yang1]. A case-control study from northeastern Iran, with 126 cases and 100 controls, was carried out to detect associations of *p21* polymorphisms (rs1801270 and rs1059234) with ESCC risk [@pone.0096958-Taghavi1]. The data suggested that these two *p21* polymorphisms, both alone and in combination, are not ESCC genetic susceptibility biomarkers, which agrees with our results.

P73, a p53 homolog, has some p53-like activities and plays an important role in modulating the cell cycle, apoptosis and DNA repair. In a high incidence region of China, *p73* polymorphisms were not associated with ESCC susceptibility [@pone.0096958-Ge1]. However, our results are more reliable because of the higher numbers of cases and controls. *p73* rs1801173 C/T polymorphism merits further functional study to elucidate the etiology of this SNP and ESCC.

The frequencies of genetic polymorphisms often vary between ethnic groups. In the present Chinese study, the allele frequency of *p21* rs3176352 C was 0.410 in 686 control subjects, which is consistent with the values reported in the SNP database for the Chinese Han (0.422) and Japanese populations (0.455), higher than that of the Sub-Saharan African (0.233) population and African American population (0.250), and but lower than that of the European population (0.758). The allele frequency of *p73* rs1801173 T was 0.230 in 686 control subjects, which is consistent with the values reported in the SNP database for the CHB+JPT (Chinese Han+Japanese) populations (0.267), higher than that of the Sub-Saharan African (0.102) population and European population (0.150).

This case-control study had several limitations. First, because the patients and controls were enrolled from hospitals, inherent bias may have resulted in spurious findings. Second, the polymorphisms we studied may not provide a comprehensive view of *p21*, *p53*, *TP53BP1* and *p73* genetic variability. Fine-mapping studies are required. Third, because of the moderate sample size and absence of a validation cohort, the statistical power was limited. Finally, the viral infections and immune parameters information was not available, thus the power of our analyses was restricted.

In conclusion, our study provides strong evidence that *p21* rs3176352 G/C and *p73* rs1801173 C/T polymorphisms may contribute to ESCC risk. Tissue-specific biological characterization and replication studies with larger populations are required to confirm our findings.
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